Cingulate Inc. Share Price
CINGCingulate Inc. Stock Performance
Open $5.50 | Prev. Close $5.28 | Circuit Range N/A |
Day Range $5.34 - $5.55 | Year Range $3.19 - $11.78 | Volume 4,798 |
Average Traded $5.46 |
Cingulate Inc. Share Price Chart
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Jun-26 | $5.50 | $5.45 | +0.00% |
30-Jun-26 | $5.50 | $5.45 | +2.44% |
29-Jun-26 | $4.95 | $5.32 | +7.47% |
26-Jun-26 | $4.80 | $4.95 | +3.77% |
25-Jun-26 | $4.86 | $4.77 | -0.63% |
24-Jun-26 | $4.86 | $4.80 | -1.64% |
23-Jun-26 | $4.87 | $4.88 | -1.21% |